Research progress of PD-1/PD-L1 signaling pathway in breast cancer
Breast cancer is the most common malignant tumor in women worldwide.The main immune escape mechanism is the dysfunction of the host immune system.In particular,programmed death-1(PD-1)inhibits T lymphocyte proliferation by binding to programmed death-ligand-1(PD-L1)to promote tumor cell immune escape.In recent years,PD-1/PD-L1 inhibitors have shown significant response and disease control to refractory metastatic breast cancer in early clinical trials of breast cancer.With the deepening of research,PD-1/PD-L1 inhibitors have been applied to the treatment of a variety of solid tumors,including melanoma,lung cancer,kidney cancer and head and neck cancer.The successful application of these inhibitors in these cancers has further stimulated widespread interest in breast cancer immunotherapy strategies and enhanced their importance in breast cancer treatment.This article aims to explore the mechanism of PD-1/PD-L1-mediated tumor immune escape and its application prospect in the treatment of breast cancer,in order to provide a new perspective and strategy for the immunotherapy of breast cancer.
breast cancerprogrammed death-1programmed death-ligand-1immunotherapy
NETL
NSTL
万方数据
